breadth occurs irrespective of demographic, virologic, or dosage factors and was associated with both transient and lasting changes to the viral quasispecies. It is of note that the neutralization improvements observed were modest in most individuals, potentially owing to the transient nature of therapy with a single antibody as well as the short time frame of observation.
Although the effect of 3BNC117 on neutralizing responses to heterologous HIV-1 viruses may seem surprising, antibodies to HIV-1 have been associated with enhanced immunity in infants born to HIV-1-infected mothers that have circulating antibodies to HIV-1 and macaques treated with monoclonal antibodies or neutralizing serum (29) (30) (31) .
How passively administered antibodies to HIV-1 accelerate the emergence of bNAbs is not completely understood. One possibility is that 3BNC117 infusion selected for viral variants with altered antigenic properties, which in turn stimulated new B cell lineages (23) (24) (25) (32) (33) (34) . A second possibility is that immune complexes formed by 3BNC117 and circulating viruses act as potent immunogens, a phenomenon that is believed to be responsible for the enhanced CD8 + T cell immunity to tumor antigens in individuals receiving monoclonal antibody-based immunotherapy (35) (36) (37) .
Irrespective of the mechanism(s), the enhanced antibody response found in individuals receiving 3BNC117 therapy indicates that immunotherapy boosts host immunity to HIV-1. Moreover, the finding that antibody responses to heterologous tier 2 viruses develop in nearly all 3BNC117-treated individuals suggests that host genetics or a specific viral envelope sequence do not limit the development of neutralizing antibodies to HIV-1. (1, 2) . In humans, a single infusion of 3BNC117, a bNAb that targets the CD4-binding site on the HIV-1 envelope glycoprotein gp160, led to a rapid but transient reduction in viral loads by an average of 1.48 log 10 copies per ml (3).
HIV-1 ANTIBODIES
Antibodies differ from small-molecule drugs that interfere with viral replication in that antibodies have the potential to affect the half-lives of both free virus and infected cells. Indeed, antibodies accelerate the clearance of free virions from the blood of macaques (4) and induce killing of infected cells in vitro by Fcg receptor (FcgR)-mediated mechanisms (5, 6). However, the majority of infected cells die rapidly by apoptosis SCIENCE sciencemag.org or pyroptosis (7, 8) , and whether bNAbs can accelerate HIV-1-infected cell clearance in vivo has not been tested directly.
To examine the components that contribute to viral clearance in humans given a single infusion of 3BNC117, we adapted an existing model of HIV-1 viral dynamics (3, 9, 10) . The model (11) (fig. S1 ) includes virus-producing infected cells, as well as transport of free plasma virus to lymphoid tissues (LTs) and vice versa. To this basic model, we added the feature that antibodies bind to virus particles, which leads to virus neutralization and loss of antibody. Measurements of the decline of antibody concentrations in healthy humans were fitted to a two-compartment model (12, 13) to obtain the parameters characterizing the intrinsic antibody decay rates and transport between tissue and plasma over the time scale during which viral loads decay in patients treated with 3BNC117 ( fig. S2 ). The rate of free virus neutralization was fitted to the virus kinetics in 19 patients ( fig. S3 ), but we focused on patients showing an initial monophasic viral load decline (2B3, 2C1, 2C5, 2D3, 2E1, and 2E2), which tended to coincide with those receiving a higher antibody dose (3) .
This model is unable to recapitulate the kinetics of viral load decline for any of the 3BNC117-treated viremic patients ( Fig. 1, green; and fig.  S3 ). If we fit the overall extent of viral load decrease, the rate of viral load decay is predicted to be too fast. Conversely, matching the initial rate of viral load decline results in insufficient overall reduction of the viral load. Thus, we adjusted our model to incorporate a mechanism that includes antibodies acting to clear infected cells and explored the revised model to see if it provided additional reduction of virus over a longer time scale (11) . The rates of free-virus neutralization and infected cell clearance are fit to the measured plasma viral load. Including cell clearance substantially improves the fit to patient data ( Fig. 1, purple; fig. S3 ; and table S3), because reducing the number of infected cells in tissues results in a second-order decay in the plasma viral load over a longer time scale.
Our modeling clearly shows that the patient data cannot be explained if 3BNC117 acts only to neutralize free virions and thus makes them incapable of infecting target cells. Including infected cell clearance improves the fit but does not quantitatively recapitulate the data; the reasons for these results are noted in the supplementary materials (11) . Further evidence for such a mechanism is indicated by comparison of our modeling and clinical data for patients treated with a constant high level of entry-inhibitor drugs like maraviroc (11, 14) (fig. S4 ).
To determine whether 3BNC117 can recognize the HIV-1 envelope (Env) trimer expressed on the surface of infected cells, we stained CD4 + T cells infected with HIV-1 YU2 or primary isolates obtained from patients 2C1, 2C5, 2D3, and 2E5 before they were infused with 3BNC117 (3). Consistent with their neutralizing activity in TZM-bl assays, 3BNC117, PG16, and 10-1074 specifically stained HIV-1 YU2 -infected cells ( fig. S5A ). Also, 3BNC117 and 10-1074 recognized nearly all Gag + cells infected with primary isolates from patients 2C1, 2C5, 2D3, and 2E5; however, the mean fluorescence intensity of staining for Env was lower than for HIV-1 YU2 (fig. S5B) 
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null (NRG mice). To prevent spread of infection between human cells, animals and infected cell suspensions were treated with antiretroviral therapy (ART) before adoptive transfer. Anti-HIV-1 bNAbs or isotype control antibodies were administered 12 hours before infected cell transfer ( fig. S6 ).
Either 3BNC117 alone (P = 0.0012) ( Fig. 2A ) or a combination of 3BNC117 and 10-1074 rapidly reduced the percentage of HIV-1 YU2 -infected cells among CD3 +
CD8
-cells compared with that in mice treated with an isotype control (P < 0.0001) (Fig. 2B) . Concomitant with reduction in the percentage of infected cells, cell-associated HIV-1 RNA levels were lower in bNAb-treated mice than in those treated with isotype controls (P = 0.0054) (Fig. 2B ). These data indicate that bNAbs can accelerate clearance of HIV-1 YU2 -infected cells in vivo. Within each subfigure, we note the quantity Dlog 10 V P (t min ) = log 10 [V P,min /V P (0)], i.e., the viral load at the nadir and the time in days at which this occurs for the data (black letters), as well as the predictions for a model with free virus clearance only (green) and for a model that also includes infected cell clearance (purple). This predicted minimum for each patient and model is denoted with a star.
To determine whether HIV-1-specific antibodies can accelerate clearance of cells infected with primary HIV-1 isolates, we repeated the adoptive transfer experiment described above using human CD4 + T cells infected with HIV 2C1 , HIV 2C5 , HIV 2D3 , or HIV 2E5 . As with HIV-1 YU2 , bNAbs accelerated clearance of cells infected with patient isolates (Fig. 2C) . We conclude that bNAbs can accelerate clearance of CD4 + T cells infected with primary HIV-1 isolates.
To determine whether enhanced clearance of HIV-infected cells by antibodies depends on their ability to engage FcgR-expressing cells, we repeated the adoptive transfer experiments using bNAbs that carry mutations that specifically abrogate mouse FcgR binding [Arg substituted for Gly 236 and for Leu 328 (G236R/L328R or GRLR)] (16) (fig. S7) . Although GRLR-bNAbs show normal levels of neutralizing activity in TZM-bl assays (17), they do not interact with cytotoxic or phagocytic cells and should therefore fail to accelerate clearance of HIV-1-infected cells in vivo.
The frequency of infected cells remaining after treatment with GRLR-bNAbs was comparable to that found in mice receiving the isotype control (Fig. 3A) and significantly higher than that found in mice receiving wild-type bNAbs (P < 0.0001) (Fig. 3A) . In addition to testing GRLR-bNAbs, we also blocked wild-type bNAb Fc-FcgR interactions using a combination of antibodies 2.4G2 and 9E9, targeting mouse FcgRs II/III and IV, respectively ( fig. S7 ). Mice receiving FcgR-blocking antibodies failed to accelerate clearance of HIV-1-infected cells in response to bNAbs (Fig. 3B) .
Human immunoglobulin-G1 (IgG1), the isotype of 3BNC117 and 10-1074, binds with highest affinity to mouse FcgRI and FcgRIV (mFcgRI and mFcgRIV) (18) . These receptors are murine orthologs of human FcgRI and FcgRIII (hFcgRI and hFcgRIII) (19) , which are expressed on human monocytes and natural killer (NK) cells that can perform antibody-dependent cell-mediated phagocytosis (ADCP) or cytotoxicity (ADCC) in vitro (5) . To examine the role of mFcgRIV in clearance of HIV-1-infected cells in the NRG mouse, we blocked this receptor specifically with an mFcgRIV-specific monoclonal antibody (anti-mFcgRIV). Mice treated with bNAbs plus anti-mFcgRIV were comparable to isotype-treated mice (Fig. 3C) , which indicated that mFcgRIV is essential for accelerating clearance of HIV-1 YU2 -infected cells in vivo. We conclude that bNAbs accelerate infected cell clearance in NRG mice by a mechanism that requires mFcgRIV engagement.
We repeated adoptive transfer experiments in FcgR-humanized (hFcgR) mice that express only the human FcgRs (20) . Similar to NRG mice, HIV-1 YU2 -infected cells were reduced in bNAbtreated hFcgR mice (P = 0.0064) (fig. S8 ). These data suggest that bNAbs can use human FcgRs and not just murine FcgRs to accelerate clearance of HIV-1 YU2 -infected cells in vivo.
To examine whether 3BNC117 accelerates clearance of HIV-1-infected cells in the context of chronic viral infection, we performed hemisplenectomy experiments in chronically infected SCIENCE sciencemag.org Data represent two to four independent experiments with a total of 6 to 13 mice per condition. *P < 0.05; **P < 0.005; ***P < 0.001; two-tailed Mann-Whitney U test. humanized mice (fig. S9 ). The frequency of HIV-1 YU2 -infected cells before treatment was comparable in all groups of mice ( fig. S10 ). As expected, mice treated with the Fc mutant antibody GRLR-3BNC117, which neutralizes HIV-1 but does not interact with effector cells, had lower frequencies of infected cells compared with isotype-treated controls (P = 0.0219) (Fig. 3D) . However, mice treated with wild-type 3BNC117, which can mediate ADCC and ADCP, had substantially fewer infected cells compared with mice treated with GRLR-3BNC117 (P = 0.0167) (Fig. 3D) . These data suggest that 3BNC117 can accelerate clearance of HIV-1 YU2 -infected cells in the context of chronic viral infection. In contrast to ART, antibodies have the potential to engage host immune cells in defense against the virus. They do so by binding to cellfree virions, which accelerates clearance and prevents their entry into target cells. Antibodies can also bind to HIV-1 Env on the surface of infected cells to induce ADCC or phagocytosis. Finally, immune complexes can activate antigenpresenting dendritic cells to elicit adaptive immune responses (19) .
Both neutralizing and non-neutralizing antibodies support anti-HIV-1 ADCC activity in vitro (5, 21) , and Fc receptor binding is essential for optimal protection, postexposure prophylaxis, and therapy by bNAbs in animal models (17, 18, (22) (23) (24) . Moreover, ADCC has been indirectly associated with both control of and protection against infection (15, (25) (26) (27) (28) . However, the rapid death of HIV-1-infected cells has made it difficult to establish that antibodies can accelerate the clearance of infected cells in vivo. Our mathematical analysis of patient data, and the antibody-mediated reduction in infected cells seen in adoptive transfer experiments, establish that bNAbs alter the half-life of infected cells. This observation may help explain why postexposure prophylaxis with bNAbs is more effective than ART in hu-mice (23) .
Experiments with human cells in mice cannot fully recapitulate the human host; nevertheless, these experiments establish that antibodies can accelerate clearance of infected cells in vivo and do so by an FcgR-dependent mechanism. The finding that antibodies can clear infected cells in vivo has important implications for therapies aimed at HIV prevention and viral reservoir reduction or elimination.
